Análisis Argos
PRVA
PRVACara
Privia Health Group, Inc. · Healthcare
US$ 27.36
precio al 2026-07-04
Valor justo Argos*
US$ 17–18
vs. su valor justo
54% por encima
Score Argos
52/100
LA RESPUESTA
El mercado le pide crezca 29.3% al año — más de lo que ha demostrado (10%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
Las ganancias crecieron 59% el último año.
Tiene más caja que deuda: balance fuerte.
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
VALOR1/6FUTURO4/6PASADO3/6SALUD5/6DIVIDENDO1/6
El Iris de calidad
VALOR1/6FUTURO4/6PASADO3/6SALUD5/6DIVIDENDO1/6
ValorCotiza por encima de su valor justo
FuturoIngresos creciendo con fuerza
PasadoHistorial aceptable
SaludBalance fuerte, deuda controlada
DividendoEl dividendo aún duerme
Score Argos52de 100Cara
Ingresos22%
US$ 2.1 B
Margen operativo60%
1.6%
Flujo de caja libre60%
US$ 0.2 B
Deuda neta
US$ -0.5 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 3.4B
P/E150.4x
EV/EBITDA67.5x
FCF yield4.7%
ROIC8.7%
Margen operativo1.6%
Crecim. ingresos+22.3%/año
Piotroski F6/9
Novedades

Noticias recientes

fool.com · 8 jun
Privia's CEO Just Sold 121,000 Shares for $2.7 Million
CEO Parth Mehrotra sold 121,086 shares directly for a total of ~$2.73 million at an average price of around $22.56 per share across two days ending May 12, 2026. This transaction represented 21.80% of Mehrotra's direct holdings prior to the sale, reducing his direct position to 434,357 shares.
gurufocus.com · 4 jun
A Look at Privia Health Group Inc (PRVA) After 3.4% Gain -- GF Value $27.19 vs Price $21.37
On June 04, 2026, Privia Health Group Inc (PRVA) shares rose 3.4% to a current price of $21.37. Over the past 52 weeks, the stock has traded between $18.77 and
fool.com · 30 may
Is Privia Health Stock a Buy After Hedge Fund Rubicon Founders Added Over 175,000 Shares to Its Position?
Privia Health Group delivers technology-driven solutions to optimize physician practices and support value-based care nationwide.
globenewswire.com · 28 may
Cross Keys Capital Advises Neurology Group of Bergen County in Its Partnership with Privia Health
Fort Lauderdale, May 28, 2026 (GLOBE NEWSWIRE) -- Cross Keys Capital, LLC, a leading independent investment banking firm providing M&A advisory services to physician group practices and healthcare services companies,is  pleased to announce it acted as the exclusive financial advisor to the Neurology Group of Bergen County (“NGBC”) in its partnership with Privia Health. Founded in 1973, the Neurology Group of Bergen County is one of the region's most respected independent neurology practices, serving the communities of Bergen County, New Jersey.
zacks.com · 27 may
TBRG vs. PRVA: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical Info Systems sector might want to consider either TruBridge (TBRG) or Privia Health (PRVA). But which of these two stocks presents investors with the better value opportunity right now?
globenewswire.com · 27 may
Privia Health Enters New Jersey
ARLINGTON, Va., May 27, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA), a national physician enablement company, announced it has signed a definitive agreement to enter the state of New Jersey in partnership with Neurology Group of Bergen County (NGBC), a practice with 25 adult and pediatric clinicians.
zacks.com · 11 may
TBRG or PRVA: Which Is the Better Value Stock Right Now?
Investors interested in Medical Info Systems stocks are likely familiar with TruBridge (TBRG) and Privia Health (PRVA). But which of these two stocks presents investors with the better value opportunity right now?
marketbeat.com · 8 may
Privia Health Group Q1 Earnings Call Highlights
Privia Health Group NASDAQ: PRVA reported a strong first quarter, with executives pointing to double-digit provider growth, a larger value-based care population and margin expansion as signs that the company's operating model continues to scale.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.